Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA - Project - Authors - KSSG Research Database

Project

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

Ongoing - recruitment closed · 2023 until 2099

Huober Jens, Quinter Janine, Kehl Jeanine

Huober, Jens

chief physician
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I

Quinter, Janine

Medizinische Onkologie und Hämatologie · Dept. I

Kehl, Jeanine

study nurse
Medizinische Onkologie und Hämatologie · Dept. I